investorscraft@gmail.com

Intrinsic Value of Merck & Co., Inc. (MRK)

Previous Close$80.93
Intrinsic Value
Upside potential
Previous Close
$80.93

VALUATION INPUT DATA

This valuation is based on fiscal year data as of 2024 and quarterly data as of .

Data is not available at this time.

Stock Valuation Context

Business Model And Market Position

Merck & Co., Inc. is a global pharmaceutical leader specializing in innovative medicines, vaccines, and animal health products. The company operates in a highly competitive and regulated industry, with its core revenue model driven by patented pharmaceuticals, including blockbuster drugs like Keytruda, which dominates the oncology market. Merck’s diversified portfolio spans therapeutic areas such as oncology, infectious diseases, and cardiometabolic conditions, reinforcing its resilience against sector volatility. The firm maintains a strong market position through R&D excellence, strategic acquisitions, and global commercialization capabilities, ensuring sustained demand for its high-margin therapies. Merck’s animal health segment further diversifies revenue streams, capitalizing on the growing pet care and livestock markets. With a focus on biologics and precision medicine, the company is well-positioned to address unmet medical needs and leverage long-term industry tailwinds.

Revenue Profitability And Efficiency

Merck reported robust revenue of $64.2 billion for FY 2024, underpinned by strong demand for Keytruda and other key products. Net income reached $17.1 billion, reflecting a disciplined cost structure and high-margin pharmaceutical sales. Operating cash flow of $21.5 billion highlights efficient working capital management, while capital expenditures of $3.4 billion indicate sustained investment in production and R&D infrastructure.

Earnings Power And Capital Efficiency

Diluted EPS of $6.74 demonstrates Merck’s earnings strength, supported by pricing power and operational leverage. The company’s capital efficiency is evident in its ability to generate significant cash flows relative to its debt and equity base, enabling reinvestment in high-return projects and shareholder returns.

Balance Sheet And Financial Health

Merck maintains a solid balance sheet with $13.2 billion in cash and equivalents, providing liquidity for strategic initiatives. Total debt of $37.1 billion is manageable given the company’s cash flow generation and low leverage ratios. The financial structure supports ongoing R&D and potential M&A activity without compromising stability.

Growth Trends And Dividend Policy

Merck’s growth is driven by its oncology pipeline and international expansion, with Keytruda remaining a primary growth engine. The company’s dividend policy is shareholder-friendly, with a $3.10 annual dividend per share, reflecting a commitment to returning capital while retaining flexibility for growth investments.

Valuation And Market Expectations

Merck’s valuation reflects its leadership in high-growth therapeutic areas and consistent earnings performance. Market expectations are anchored on pipeline advancements and the company’s ability to offset patent expirations with new product launches, sustaining premium pricing in the biopharma sector.

Strategic Advantages And Outlook

Merck’s strategic advantages include its deep R&D expertise, global commercial footprint, and strong IP portfolio. The outlook remains positive, with opportunities in biologics and targeted therapies likely to drive long-term growth, though regulatory and competitive risks persist in the evolving pharmaceutical landscape.

Sources

Company 10-K, investor presentations

show cash flow forecast

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year2025202620272028202920302031203220332034203520362037203820392040204120422043204420452046204720482049

INCOME STATEMENT

Revenue growth rate, %NaN
Revenue, $NaN
Variable operating expenses, $mNaN
Fixed operating expenses, $mNaN
Total operating expenses, $mNaN
Operating income, $mNaN
EBITDA, $mNaN
Interest expense (income), $mNaN
Earnings before tax, $mNaN
Tax expense, $mNaN
Net income, $mNaN

BALANCE SHEET

Cash and short-term investments, $mNaN
Total assets, $mNaN
Adjusted assets (=assets-cash), $mNaN
Average production assets, $mNaN
Working capital, $mNaN
Total debt, $mNaN
Total liabilities, $mNaN
Total equity, $mNaN
Debt-to-equity ratioNaN
Adjusted equity ratioNaN

CASH FLOW

Net income, $mNaN
Depreciation, amort., depletion, $mNaN
Funds from operations, $mNaN
Change in working capital, $mNaN
Cash from operations, $mNaN
Maintenance CAPEX, $mNaN
New CAPEX, $mNaN
Total CAPEX, $mNaN
Free cash flow, $mNaN
Issuance/(repurchase) of shares, $mNaN
Retained Cash Flow, $mNaN
Pot'l extraordinary dividend, $mNaN
Cash available for distribution, $mNaN
Discount rate, %NaN
PV of cash for distribution, $mNaN
Current shareholders' claim on cash, %NaN
HomeMenuAccount